Name: Quick Ratio

Definition: The quick ratio is like an emergency response measure: can the company pay off short-term debts without selling any inventory? It only counts cash, short-term investments, and receivables — assets that can quickly be turned into cash. A healthy quick ratio shows strong liquidity. A very low quick ratio means the company depends on selling inventory to meet short-term obligations — which can be risky if sales unexpectedly slow down.

Interpretation:
• In '2021', ACHV's quick ratio was 9.49, providing a stringent test of short-term liquidity. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at 3.61.
• In '2022', ACHV's quick ratio was 1.15, providing a stringent test of short-term liquidity. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at 2.74. Industry average declined by 0.88 from previous year.
• In '2023', ACHV's quick ratio was 0.75, providing a stringent test of short-term liquidity. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at 2.55. Industry average declined by 0.19 from previous year.
• In '2024', ACHV's quick ratio was 5.14, providing a stringent test of short-term liquidity. The increase since '2023' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at 2.69. Industry average increased by 0.15 compared to previous year.
Overall, ACHV's quick ratio has been volatile but showed a downward trend over the past 4 years.

Formula: Quick Ratio = (Current Assets - Inventory) / Current Liabilities

Good Range: Normally between 0.8 and 1.5.